Department of Biological Sciences, Konkuk University, Seoul, 143-701, Korea.
Arch Pharm Res. 2012 Mar;35(4):573-7. doi: 10.1007/s12272-012-0400-8.
Classical antidepressants elevate the monoamine levels in the brain by preventing re-uptake of monoamines after release. Treatment of depression with monoamine re-uptake inhibitors is associated with low clinical efficacy and remission rate due to the delayed onset of therapeutic responses. Therefore, the development of alternative antidepressants is essential for successful treatment of this disease. Recently, glutamate receptor antagonists including ketamine and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) have received wide attention as fast-acting therapeutic alternatives for treatment of depression.
经典的抗抑郁药通过防止单胺释放后再摄取来提高大脑中的单胺水平。由于治疗反应的延迟，使用单胺再摄取抑制剂治疗抑郁症与临床疗效和缓解率低有关。因此，开发替代抗抑郁药对于成功治疗这种疾病至关重要。最近，谷氨酸受体拮抗剂，包括氯胺酮和 2-甲基-6-(苯乙炔基)吡啶（MPEP），作为治疗抑郁症的快速作用治疗替代品受到了广泛关注。
